Ricevi le ultime notizie sulle azioni Lineage Cell Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di LCTX

Ultime notizie per

LINEAGE CELL THERAPEUTICS IN

Lineage Cell Therapeutics

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics Inc

Press Releases

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

Four Rising Stars Driving the Next Wave of Stem Cell and Gene Therapy Innovation

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss

Lineage Cell Therapeutics to Present at September 2025 Investor Conferences

Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes

ADIA

CRSP

LCTX

MESO

AC Immune

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Aura Biosciences

Benitec Biopharma

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

DiaMedica Therapeutics Inc. - Common Stock

DiaMedica Therapeutics

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences

Design Therapeutics

Editas Medicine

enGene Holdings

ETHZilla

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Immuneering Corporation - Class A Common Stock

Immuneering

Jade Biosciences

Kamada

Korro Bio

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexeo Therapeutics

Neurogene

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Rocket Pharmaceuticals, Inc. - Common Stock

Comments

Lineage Cell Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO